[{"id":"47f92e4c-0373-4b92-b1aa-e6cda3cd31e1","acronym":"","url":"https://clinicaltrials.gov/study/NCT04828486","created_at":"2021-04-02T11:53:33.440Z","updated_at":"2024-07-02T16:35:12.332Z","phase":"Phase 2","brief_title":"Futibatinib and Pembrolizumab for Treatment of Advanced or Metastatic FGF19 Positive BCLC Stage A, B, or C Liver Cancer","source_id_and_acronym":"NCT04828486","lead_sponsor":"Mayo Clinic","biomarkers":" FGF19","pipe":" | ","alterations":" FGF19 positive","tags":["FGF19"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FGF19 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Lytgobi (futibatinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 25","initiation":"Initiation: 05/07/2021","start_date":" 05/07/2021","primary_txt":" Primary completion: 05/06/2025","primary_completion_date":" 05/06/2025","study_txt":" Completion: 05/06/2025","study_completion_date":" 05/06/2025","last_update_posted":"2024-03-29"},{"id":"a2c2a881-d186-4a3f-be02-3a38da1848d0","acronym":"","url":"https://clinicaltrials.gov/study/NCT04699643","created_at":"2021-01-19T20:50:12.745Z","updated_at":"2024-07-02T16:36:36.469Z","phase":"Phase 1/2","brief_title":"FGFR4 Inhibitor EVER4010001 in Combination With PD-1 Inhibitor Pembrolizumab in Patients With Advanced Solid Tumors","source_id_and_acronym":"NCT04699643","lead_sponsor":"EverNov Medicines (Zhuhai Hengqin) Co., Ltd","biomarkers":" FGF19","pipe":" | ","alterations":" FGF19 positive • FGF19 expression","tags":["FGF19"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FGF19 positive • FGF19 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • roblitinib (FGF401)"],"overall_status":"Recruiting","enrollment":" Enrollment 80","initiation":"Initiation: 07/30/2020","start_date":" 07/30/2020","primary_txt":" Primary completion: 06/01/2023","primary_completion_date":" 06/01/2023","study_txt":" Completion: 06/01/2023","study_completion_date":" 06/01/2023","last_update_posted":"2021-01-07"}]